Immuno-oncology, which harnesses the patient’s own immune system to fight cancer, is one of the hottest areas in drug development today. In recent years, the FDA has granted breakthrough therapy designations to multiple immuno-oncology drugs for a variety of oncology indications including advanced non-small cell lung cancer and melanoma. Over the last two decades, PK/PD […]Read More
Author: Rik de Greef
Rik de Greef joined Quantitative Solutions in July 2014 as Executive Director and lead of the group in Oss, The Netherlands. Rik has been trained as a PK-PD scientist at Leiden University, The Netherlands. In 1998, he joined Organon, where he has been the key driver for the successful implementation of model based drug development approaches, supporting the development and registration of e.g. asenapine (schizophrenia & bipolar disorder) and corifollitropin alfa (fertility). Over the years, Rik has taken on roles with increasing responsibilities within Organon and its successor companies Schering-Plough and Merck/MSD. Most recently, has was site lead for Clinical PK-PD. In this role he has led the expansion of the group from 15 to 34 coworkers. Also, he has led the preparations of the early clinical components of the BLA submission for Merck’s key program in oncology, pembrolizumab. Rik’s key interests are in the integration of model based components with overall clinical pharmacology and clinical development deliverables throughout the development trajectory. He enjoys combining his analytical skills and creativity in designing efficient drug development strategies that address the right questions at the right time. In his spare time, Rik enjoys spending time with his family, and fostering his broad range of other interests: music, nature, design, food and combinations thereof.